News World first as infant gets personalised CRISPR therapy In a medical breakthrough, a child diagnosed with a rare genetic disorder has received a bespoke CRISPR gene editing therapy to correct the mutation.
News Sickle cell gene therapy Casgevy finally cleared for NHS use Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.
News Editas axes two-thirds of its staff, including its CMO Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.
News After a no in sickle cell, NICE OKs Casgevy for thalassaemia Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it dow
R&D Opportunity costs of gene therapies. Where do we go from her... Over 30 gene therapies have received regulatory approval.
R&D The innovative future of CRISPR tech CRISPR-based therapies have moved from theory to reality, after the recent landmark approval of the first such treatment by the FDA.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face